LifeNet Health
LifeNet Health is a global leader in regenerative medicine, dedicated to saving lives, restoring health, and giving hope through innovative solutions such as allograft bio-implants, cellular therapies, and life sciences solutions. With a history spanning over 40 years, the organization focuses on providing safe, effective, and high-quality grafts and supporting scientific research to improve patient outcomes worldwide.
Industries
Nr. of Employees
large (251-1000)
LifeNet Health
1864 Concert Drive, Virginia Beach, VA 23453-1903
Patents
Products
Cellular bone matrix (cryopreserved viable bone cells in corticocancellous matrix)
Cryopreserved human bone graft material containing viable, lineage-committed bone-forming cells within a corticocancellous matrix combined with demineralized bone to provide osteogenic, osteoconductive, and osteoinductive properties for fusion, nonunion, and reconstruction.
Demineralized bone fibers (moldable bone fiber product)
100% demineralized bone fibers engineered to interlock and become moldable upon rehydration without the use of a carrier, intended to encourage bone formation and handling versatility.
Decellularized dermal matrix (porous dermal graft for wound management)
Porous decellularized dermal grafts processed to provide soft-tissue coverage and support wound healing in chronic and acute wound indications.
Decellularized vascular graft (arterial conduit)
Decellularized arterial graft intended for use as a conduit for blood flow in peripheral vascular and bypass applications.
Textured allograft wedge for foot and ankle reconstruction
Textured structural allograft wedge engineered to resist graft migration and subsidence for foot and ankle surgical procedures.
Decellularized placental membrane graft
Naturally intact decellularized placental membrane grafts that incorporate structural layers for use in treating surgical wounds, diabetic ulcers, and burns; processed to preserve relevant trophoblast layer structures.
Cellular bone matrix (cryopreserved viable bone cells in corticocancellous matrix)
Cryopreserved human bone graft material containing viable, lineage-committed bone-forming cells within a corticocancellous matrix combined with demineralized bone to provide osteogenic, osteoconductive, and osteoinductive properties for fusion, nonunion, and reconstruction.
Demineralized bone fibers (moldable bone fiber product)
100% demineralized bone fibers engineered to interlock and become moldable upon rehydration without the use of a carrier, intended to encourage bone formation and handling versatility.
Decellularized dermal matrix (porous dermal graft for wound management)
Porous decellularized dermal grafts processed to provide soft-tissue coverage and support wound healing in chronic and acute wound indications.
Decellularized vascular graft (arterial conduit)
Decellularized arterial graft intended for use as a conduit for blood flow in peripheral vascular and bypass applications.
Textured allograft wedge for foot and ankle reconstruction
Textured structural allograft wedge engineered to resist graft migration and subsidence for foot and ankle surgical procedures.
Decellularized placental membrane graft
Naturally intact decellularized placental membrane grafts that incorporate structural layers for use in treating surgical wounds, diabetic ulcers, and burns; processed to preserve relevant trophoblast layer structures.
Services
Facilitation of organ, tissue, and placenta donation through hospital partnerships, including donor screening and sample collection workflows.
On-site bio-implant specialist consultation and customer service for implanting surgeons and facilities, plus emergency on-call support.
Provision of human cell- and tissue-based research materials and contract research services with defined policies for direct cost coverage and limited overhead reimbursement for external investigators.
Multi-site production and logistics including bi-coastal processing and centralized distribution to support product availability and shipping.
Facilitation of organ, tissue, and placenta donation through hospital partnerships, including donor screening and sample collection workflows.
On-site bio-implant specialist consultation and customer service for implanting surgeons and facilities, plus emergency on-call support.
Provision of human cell- and tissue-based research materials and contract research services with defined policies for direct cost coverage and limited overhead reimbursement for external investigators.
Multi-site production and logistics including bi-coastal processing and centralized distribution to support product availability and shipping.
Expertise Areas
- Regenerative medicine and orthobiologics
- Allograft processing and tissue engineering
- Cellular therapy product development
- Demineralized bone and osteoinductive materials
Key Technologies
- Decellularization of soft tissues
- Demineralization of bone matrix
- Cryopreservation of viable human cells
- Aseptic tissue processing
News & Updates
LifeNet Health announced the introduction of Nexeon, a decellularized femoral artery for vascular procedures, on June 4, 2025.
On April 23, 2025, LifeNet Health announced the nationwide availability of Dermacell® Porous, a breakthrough in wound management.
The organization was honored with an Excellence in Practice Award by the Association for Talent Development in June 2025.
Longest Running Accreditation by AATB
LifeNet Health holds the longest current accreditation by the American Association of Tissue Banks (AATB).
FDA Clearance for Cardiograft Cardiac Patch with Matracell
Received FDA clearance in 2008 for the Cardiograft Cardiac Patch with Matracell.
Numerous U.S. Patents in Regenerative Medicine
Developed proprietary and patented cleaning, demineralization, and composite allograft technologies.
LifeNet Health announced the introduction of Nexeon, a decellularized femoral artery for vascular procedures, on June 4, 2025.
On April 23, 2025, LifeNet Health announced the nationwide availability of Dermacell® Porous, a breakthrough in wound management.
The organization was honored with an Excellence in Practice Award by the Association for Talent Development in June 2025.
Longest Running Accreditation by AATB
LifeNet Health holds the longest current accreditation by the American Association of Tissue Banks (AATB).
FDA Clearance for Cardiograft Cardiac Patch with Matracell
Received FDA clearance in 2008 for the Cardiograft Cardiac Patch with Matracell.
Numerous U.S. Patents in Regenerative Medicine
Developed proprietary and patented cleaning, demineralization, and composite allograft technologies.